A Phase I Trial of Ipilimumab Plus Bevacizumab in Patients with Unresectable Stage Iii or Stage Iv Melanoma

F. S. Hodi,P. A. Friedlander,M. B. Atkins,D. F. McDermott,D. P. Lawrence,N. Ibrahim,X. Wu,J. Zhou,A. Giobbie-Hurder,G. Murphy,T. Hollman,E. Velazquez,S. Russell,P. Dipiro,J. T. Yap,A. D. Van den Abbeele
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8511
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:8511 Background: CTLA-4 blockade with ipilimumab demonstrated a survival advantage in advanced melanoma. Ipilimumab induces an immune mediated tumor vasculopathy. In addition to angiogenic effects, VEGF is a potent immune suppressor of antigen presenting cells. Therefore, we performed the first combination study to investigate potential synergies of ipilimumab and bevacizumab. Methods: Patients (pts) were eligible with stage III unresectable or stage IV disease, no bowel or CNS metastases, ECOG PS 0 or 1, > 4 wks from prior therapy, adequate end organ function, no autoimmune or bleeding problems. Pts received ipilimumab every 3 weeks IV x 4 then q12 weeks, and bevacizumab q 3 weeks. Pts could continue if good PS with up to 40% increase in the sum of the longest diameter and no more than 2 new target lesions. Cohort 1 comprised 10 mg/kg ipilimumab plus 7.5 mg/kg bevacizumab. If ≥3/5 pts did not experience DLT then cohort 2 could be enrolled at 10 mg/kg ipilimumab plus 15 mg/kg bevacizumab. An additional 12 patients could be treated at MTD. Results: 22 pts treated with 21 pts currently evaluable. Side effects included giant cell arteritis(1), hypophysitis(3), thyroiditis(4), grade 3-4 hepatitis(2), bilateral uveitis(2), and grade 2 colitis(2); 5 pts required systemic steroids and stopping treatment. All toxicities resolved. PET revealed early response activity and perfusion CT demonstrated persistent decreased tumor blood flow. Best overall response to date includes 8 partial responses and 6 stable disease. All responses are durable (>6mos). Median TTP has not yet been achieved. Post-treatment biopsies in 12 pts revealed activated vessel endothelium with extensive T cell trafficking not seen with ipilimumab alone, as well as non-productive central angiogenesis. Peripheral blood monitoring revealed marked increase in CD4/CCR7/CD45RO central memory cells in majority of patients, not seen with ipilimumab alone. Conclusions: Ipilimumab plus bevacizumab can be safely administered, with management of noted toxicities. Clinical activity and correlatives suggest synergistic effects, with 14/21 pts experiencing clinical benefit. This combination merits further exploration, with additional efforts underway.
What problem does this paper attempt to address?